How novel anticoagulants compare with warfarin for intraocular bleedingHow do the newer anticoagulant medications compare with warfarin when it comes to the risk of intraocular bleeding? A meta-analysis published in JAMA Ophthalmology did a systematic review of phase 3 randomized trials looking at over 100,000 patients.
Anticoagulant use in URS patients ups bleeding riskPatients undergoing ureteroscopy while remaining on anticoagulant therapy may be at increased risk for bleeding complications, including significant bleeding events and unplanned returns to the operating room, according to a retrospective study
Use new data to inform unique patient group"Increasingly, urologists are faced with patients who cannot safely discontinue anticoagulation or antiplatelet medications, even in the face of an impending surgical procedure. This is a trend that is likely to continue into the foreseeable future," writes Brian R. Matlaga, MD, MPH.
Mail order boosts med adherence for stroke patientsStroke patients were more adherent to mail order prescriptions versus picking up their medications at retail pharmacies, according to new research presented at the recent International Stroke Conference in Los Angeles, Calif.
FDA approves first reversal agent for anticoagulant PradaxaFDA has approved idarucizumab (Praxbind, Boehringer Ingelheim) as the first reversal agent for Pradaxa.
Investigational drug reverses anticoagulant effect of dabigatran in minutes: StudyUse of investigational reversal agent idarucizumab can allow physicians to focus on other vital aspects of emergency management beyond anticoagulant reversal in dabigatran-treated patients, according to a study published in the New England Journal of Medicine.
Is digoxin a last resort in Afib?Until another trial is conducted, digoxin use for patients who have other alternatives appears to be contraindicated.
DVT patients taking rivaroxaban had fewer hospital admissions, costs, similar subsequent hospital visits vs. standard of carePatients diagnosed with deep vein thrombosis (DVT) and treated with rivaroxaban (Xarelto) were admitted to the hospital less frequently than those treated with the standard treatment of low-molecular-weight heparin (LMWH) and warfarin, according to real-world data presented at the Hospital Medicine 2015 Congress.
Fondaparinux beats heparin in major studyThe anticoagulant medication Fondaparinux (Arixtra) was associated with reduced major bleeding events and improved survival, compared to low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non–ST-segment elevation myocardial infarction (NSTEMI), according to a new study.
Study evaluates use of novel oral anticoagulants in ICUApproximately one-third of patients on a novel oral anticoagulant (NOAC) received inappropriate dosing based on indication, renal function, or concomitant interacting medications during hospitalization in the intensive care unit, typically for stroke prevention in atrial fibrillation, according to data presented at the Society of Critical Care Medicine meeting in Phoenix.